These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 29153415

  • 21. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 22. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
    Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z, TRIDENT study investigators.
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [Abstract] [Full Text] [Related]

  • 26. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.
    Meyer T, Reitmeir P, Brand P, Herpich C, Sommerer K, Schulze A, Scheuch G, Newman S.
    Respir Med; 2011 Jun; 105(6):900-6. PubMed ID: 21397483
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Tiotropium plus formoterol versus tiotropium alone for stable moderate-to-severe chronic obstructive pulmonary disease: A meta-analysis.
    Zou Y, Xiao J, Lu XX, Xia ZA, Xie B, Li J, Chen Q.
    Clin Respir J; 2018 Jan; 12(1):269-278. PubMed ID: 27402142
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y, Nishimura N, Maezawa K, Terajima T, Kizu J, Chohnabayashi N.
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [Abstract] [Full Text] [Related]

  • 33. Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study.
    Kamei T, Nakamura H, Nanki N, Minakata Y, Matsunaga K, Mori Y, for Command Study Group.
    BMJ Open; 2019 Jul 26; 9(7):e024114. PubMed ID: 31350236
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD.
    Canto ND, Ribeiro JP, Neder JA, Chiappa GR.
    Respir Med; 2012 Oct 26; 106(10):1404-12. PubMed ID: 22748747
    [Abstract] [Full Text] [Related]

  • 36. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y, Samoro R, Fassakhov R, Taniguchi H, Ekelund J, Carlsson LG, Ichinose M.
    Respirology; 2013 Jul 26; 18(5):866-73. PubMed ID: 23551359
    [Abstract] [Full Text] [Related]

  • 37. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
    Bölükbas S, Eberlein M, Eckhoff J, Schirren J.
    Eur J Cardiothorac Surg; 2011 Jun 26; 39(6):995-1000. PubMed ID: 20970351
    [Abstract] [Full Text] [Related]

  • 38. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.
    Salvi S, Brashier B, Gothi D, Karkhanis V, Madas S, Gogtay J, Joshi J.
    Pulm Pharmacol Ther; 2014 Feb 26; 27(1):90-5. PubMed ID: 23752057
    [Abstract] [Full Text] [Related]

  • 39. Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease.
    Matsushima S, Inui N, Yasui H, Kono M, Nakamura Y, Toyoshima M, Shirai T, Suda T.
    Pulm Pharmacol Ther; 2015 Feb 26; 30():11-5. PubMed ID: 25445929
    [Abstract] [Full Text] [Related]

  • 40. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS, Morjaria JB.
    Ther Adv Respir Dis; 2015 Apr 26; 9(2):56-68. PubMed ID: 25754881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.